U.S. Bill Drafted To Require More FDA Visits To Foreign Plants
This article was originally published in PharmAsia News
Executive Summary
Draft legislation in the U.S. House would require inspections of drug-manufacturing plants in China and elsewhere in Asia as frequently as they are conducted in the United States